Gabriela Hobbs, MD, Massachusetts General Hospital, Boston, MA, presents results from the Phase I AJX-101 trial (NCT06343805) investigating AJ1-11095, a first-in-class type II JAK2 inhibitor, in patients with myelofibrosis previously treated with a type I JAK inhibitor. Dr Hobbs highlights high spleen and symptom response rates and encouraging early reductions in variant allele frequency (VAF), with anemia remaining a key consideration. She also outlines the ongoing expansion phase, which includes first-line myelofibrosis and is moving towards polycythemia vera. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.